08:00 , Nov 16, 2015 |  BioCentury  |  Regulation

Scaling compassion

Nearly two years after a viral media campaign saved seven-year-old Josh Hardy's life and put demands for access to unapproved medicines on front pages, drug companies, FDA, academic bioethicists, and patient advocates are beginning to...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

ATL1102: Phase I started

Antisense began an open-label, Australian Phase I trial to evaluate 400 mg subcutaneous ATL1102 on days 1, 3 and 5 with or without G-CSF for 5 days in 10 healthy volunteers. Antisense has rights to...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

Antisense Therapeutics, Tianjin International Joint Academy of Biotechnology and Medicine deal

Antisense and the academy terminated a 2012 deal to form a JV in Hong Kong to develop Antisense's ATL1102 after the academy was unable to obtain required funding under the terms to form the JV....
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Antisense Therapeutics, Tianjin International deal

Antisense partnered with the academy to form a JV in Hong Kong to develop Antisense's ATL1102 . Antisense will own a 49% stake and provide the JV with licenses to ATL1102 IP, while the academy...
08:00 , Jan 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma; T cell lymphoma Integrin a4b1 (ITGA4; VLA-4; CD29/CD49d) An SAR study characterized a series of VLA-4...
07:00 , Jul 7, 2008 |  BC Week In Review  |  Clinical News

ISIS 107248: Phase IIa data

In a double-blind, European Phase IIa trial in 77 patients, ATL/TV1102 met the primary endpoint of a significant reduction vs. placebo in the cumulative number of new active lesions on weeks 4, 8 and 12...
08:00 , Feb 28, 2008 |  BC Innovations  |  Cover Story

Pinpointing Triggers in MS

Two recent papers identify key players in the early stages of multiple sclerosis, opening up a large class of potential therapeutic targets. A new mouse model described in...
08:00 , Feb 25, 2008 |  BC Week In Review  |  Company News

Antisense, Teva deal

Antisense granted Teva an exclusive, worldwide license to develop and market ATL1102 to treat relapsing-remitting multiple sclerosis (MS). Antisense will receive $2 million up front and is eligible for $100 million in development and sales...
08:00 , Jan 23, 2006 |  BC Week In Review  |  Clinical News

ATL-1102: Phase IIa start

The companies will restart this quarter a double-blind, placebo-controlled, German Phase IIa trial in 80 relapsing-remitting MS patients with 400 mg weekly subcutaneous ATL1102 . The trial was halted last year due to safety concerns...